Pyxis Oncology Reports Q2 2026 Financial Results

What Happened
Pyxis Oncology, Inc. announced its financial results for the quarter ended June 30, 2026 and provided a corporate update via a press release issued August 13, 2026. The company furnished that press release as Exhibit 99.1 to a Current Report on Form 8-K (Item 2.02) filed the same day; the report was signed by Jitendra Wadhane, Principal Financial and Accounting Officer.

Key Details

• Press release dated August 13, 2026 was furnished as Exhibit 99.1 to the Form 8-K.
• The filing covers results for the quarter ended June 30, 2026 (quarterly results / earnings information).
• Form 8-K items reported: Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits).
• The report was signed on August 13, 2026 by Jitendra Wadhane (Principal Financial and Accounting Officer). No executive departures or changes (e.g., CEO/CFO) were disclosed in this filing.

Why It Matters
This filing is a routine SEC disclosure that signals Pyxis has released its latest quarterly earnings and company update; investors should read the furnished press release (Exhibit 99.1) for specifics on revenue, net results, cash position, and any business or pipeline updates. Because the Form 8-K does not itself include financial line-item detail, the press release is the primary source for assessing the quarter’s impact on earnings and outlook.